Methylprednisolone Acetate Injection Shortage Status
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA lists Methylprednisolone Acetate Injection as current in their shortage database, but it is available from Pfizer Inc.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Methylprednisolone Acetate Injection.
Methylprednisolone Acetate Injection Shortage
What's in Shortage
The generic drug name is Methylprednisolone Acetate Injection, with brand name DEPO-MEDROL. It is available in injection dosage form and is categorized under rheumatology. The current status is listed as current in the FDA database, with the shortage initially posted on 12/15/2021 and last updated on 03/27/2026.
Which Manufacturers Are Affected
Pfizer Inc. is the manufacturer affected. Their availability status is available for various presentations, including Depo-medrol Injection 40 mg/1 mL (NDC 0009-3073-01), 80 mg/1 mL (NDC 0009-3475-01), and others as listed. Contact information for Pfizer Inc. is 844-646-4398.
Why There's a Shortage
No specific reason was given for the shortage.
What Patients Should Do
Patients should speak with their pharmacist or healthcare provider to check the availability of Methylprednisolone Acetate Injection. They may also contact the manufacturer directly using the provided information. Patients should consult their healthcare provider for any medical advice, as this article does not provide recommendations on alternatives or dosing.
Source
This information is attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,241 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.